GBA2 and nasopharyngeal carcinoma: Why reducing GSL levels with miglustat or inhibiting GBA2, an additional target of miglustat,34 in NPC is therapeutically beneficial is still poorly understood in NPC, and is equally enigmatic in Tangier disease.